Kolexia
Pointreau Yoann Oncologie radiothérapie
Pointreau Yoann
Oncologie radiothérapie
Centre hospitalier de Tours
Tours, France
356 Activités
3 K Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de la tête et du cou Carcinomes Carcinome épidermoïde Carcinome épidermoïde de la tête et du cou Métastase tumorale Récidive tumorale locale Lésions radiques Métastase lymphatique Tumeurs du poumon

Collaborateurs

Voir plus
Thariat Juliette
Thariat Juliette
Centre François-Baclesse, Caen, France
Calais Gilles
Calais Gilles
Centre hospitalier de Tours, Tours, France
Sire Christian
Sire Christian
Hôpital du Scorff, Lorient, France
Denis Fabrice
Denis Fabrice
Gcs Medecine Nucleaire Sarthe_et Siege, Le Mans, France

Industries

Voir plus
MSD
33 collaboration(s)
Dernière en 2023
Merck-Serono
13 collaboration(s)
Dernière en 2023
BMS
10 collaboration(s)
Dernière en 2023
Novartis
10 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
SALTORL: Phase III Trial of Laryngeal Preservation Comparing Induction Chemotherapy With Cisplatin, 5-fluorouracil and Docetaxel (TPF) Followed by Radiotherapy and Concomitant Administration of Radiotherapy With Cisplatin
Essai Clinique (Groupe d'Oncologie Radiothérapie Tête Et Cou)   06 mars 2024
XXL_2022-01: A Double-blind, Randomized, Phase III Study of Radiotherapy Combined With cetuXimab + Xevinapant Compared to Radiotherapy Combined With Cetuximab (Standard of Care) + Placebo in Patients With LA SCCHN, Unfit for High-dose Cisplatin
Essai Clinique (Groupe d'Oncologie Radiothérapie Tête Et Cou)   06 mars 2024
FIBROTHERME: Evaluation of the Medical Benefit of a Spa Therapy on the Evolutionary Genius of Late Sequelae Fibrosis After Postoperative Radiotherapy for Breast Cancer in Remission
Essai Clinique (Floralis)   05 mars 2024
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
The Lancet. Healthy longevity   05 mars 2024
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION): A Randomized, Double-blind, Placebo-controlled, 2-arm Phase III Study to Assess Efficacy and Safety of Xevinapant and Radiotherapy Compared to Placebo and Radiotherapy for Demonstrating Improvement of Disease-free Survival in Participants With Resected Squamous Cell Carcinoma of the Head and Neck, Who Are at High Risk for Relapse and Are Ineligible for High-dose Cisplatin (XRAY VISION)
Essai Clinique (Emd Serono)   05 mars 2024
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412): A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412)
Essai Clinique (Merck & Co.)   21 février 2024
ELAN-UNFIT: Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation
Essai Clinique (Merck-Serono)   07 février 2024
Stereotactic body radiation therapy for adrenal gland metastases: A multi-institutional outcome analysis.
Clinical and translational radiation oncology   07 décembre 2023
PS3-3 Pembrolizumab + chemoradiation therapy for locally advanced head and neck squamous cell carcinoma (HNSCC): KEYNOTE-412
2023 the Japanese Society of Medical Oncology Annual Meeting. 16-18 March 2023, Kyoto, Japan   01 novembre 2023
PembroMetaRT: Randomized Trial of Loco-regional Radiotherapy Added to Pembrolizumab Alone or With Chemotherapy Versus Systemic Treatment Alone for Patients With Newly Diagnosed Head and Neck Squamous Cell Carcinoma With Synchronous Metastases
Essai Clinique (Unicancer)   12 octobre 2023